Watchlist
GHK-Cu
No lawful US route recorded
No lawful US supply route is recorded for GHK-Cu. The register therefore holds no priced programs for GHK-Cu, and this page exists so that absence is a recorded statement rather than a gap in an index.
What we hold
- Priced programs
- 0
- Status recorded
- August 31, 2026
US supply-route status was reviewed on 2026-08-31 and is recorded here as one of three states. Approved: an FDA-approved product of that molecule is marketed. Compoundable: no approved product, and compounding is permitted under section 503A. None: no lawful US supply route was found. A compounded preparation is never itself an FDA-approved product.
If that changes
If a US telehealth company begins selling GHK-Cu through a lawful route, it gets an entry here on the same terms as every other program: the price with the company’s own sentence beside it, the page it was read from, the date, the pharmacy where one is named, and the terms it is sold on. Nothing is written up in advance.
We do not publish dosing, protocols, or claims about what any molecule does. This is a record of what is sold and at what price, not clinical guidance, and how entries are recorded sets out exactly what we will and will not put in one.